Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The UK clinical-stage drug delivery Company focused on the localised and sustained delivery of chemotherapy drugs has been awarded a grant.</li>
<li>The non-dilutive research and development grant is for up to £99,902 and is from Invest Northern Ireland.</li>
<li>The grant represents 61% of eligible project expenditure, to support the continued development of its docetaxel-ChemoSeed programme for the treatment of prostate cancer. </li>
</ul>


The UK clinical-stage drug delivery Company focused on the localised and sustained delivery of chemotherapy drugs has been awarded a grant.
The non-dilutive research and development grant is for up to £99,902 and is from Invest Northern Ireland.
The grant represents 61% of eligible project expenditure, to support the continued development of its docetaxel-ChemoSeed programme for the treatment of prostate cancer. 


<ul>
<li>capAI 1.16p £2.91m (CPAI.L) The AI developer reports a strategic update at its AGM.</li>
<li>There is continued strong execution across its platform portfolio, which is entering a key inflection point, with multiple products transitioning from development into live user availability.</li>
<li>The sector focus is across preventative health, media platforms and the development and commercialisation of associated content. </li>
</ul>


capAI 1.16p £2.91m (CPAI.L) The AI developer reports a strategic update at its AGM.
There is continued strong execution across its platform portfolio, which is entering a key inflection point, with multiple products transitioning from development into live user availability.
The sector focus is across preventative health, media platforms and the development and commercialisation of associated content. 


<ul>
<li>Post a reverse in May 2024 at 11p into Amur Minerals, this UK clinical stage implantable drug delivery Company is focused on the localised and sustained delivery of chemotherapy drugs.</li>
<li>Curative cancer treatments are urgently required and the ChemoSeed platform enables the sustained delivery of chemotherapy drugs exactly where they are needed, so treatments become less toxic to the patient, while also improving performance and costeffectiveness.</li>
<li>ChemoSeed, CRISM's lead product, can be implanted directly into the tumour, so therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue. </li>
</ul>


Post a reverse in May 2024 at 11p into Amur Minerals, this UK clinical stage implantable drug delivery Company is focused on the localised and sustained delivery of chemotherapy drugs.
Curative cancer treatments are urgently required and the ChemoSeed platform enables the sustained delivery of chemotherapy drugs exactly where they are needed, so treatments become less toxic to the patient, while also improving performance and costeffectiveness.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour, so therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue. 


<ul>
<li>The supplier of sustainable wood building materials provided a trading update for the five months ended 31 August.</li>
<li>Accsys reported revenue of EUR 56.9m for the five months ended 31 August, down 6% from EUR 60.4m.</li>
<li>Trading in the first five months of FY27 has started slower than expected due to inflationary pressures, interest rate increases, cautious purchasing patterns, delayed project activity and reduced consumer confidence. </li>
</ul>


The supplier of sustainable wood building materials provided a trading update for the five months ended 31 August.
Accsys reported revenue of EUR 56.9m for the five months ended 31 August, down 6% from EUR 60.4m.
Trading in the first five months of FY27 has started slower than expected due to inflationary pressures, interest rate increases, cautious purchasing patterns, delayed project activity and reduced consumer confidence. 


Mothercare plc - Small Cap Feast: 21 September 2026

<ul>
<li>Arecor Therapeutics 62.50p £22.47m (AREC.L) The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity &amp; Metabolism.</li>
<li>The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy.</li>
<li>This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.</li>
</ul>


Arecor Therapeutics 62.50p £22.47m (AREC.L) The clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces the publication of clinical data from its AT278-104 study published in the peer-reviewed Diabetes, Obesity &amp; Metabolism.
The study demonstrated that AT278, Arecor's investigational ultra-concentrated (500U/mL or U500) insulin aspart formulation, maintained its ultra-rapid pharmacokinetic and pharmacodynamic profile regardless of body mass index levels, supporting its potential as the first ultra-rapid U500 insulin for people with insulin-resistant type 2 diabetes who require high-dose therapy.
This article marks the first time the complete study results have been published in a peer-reviewed scientific journal, following presentations at the annual meeting of the European Association for the Study of Diabetes and the American Diabetes Association's Scientific Sessions.


United Kingdom

Crism Therapeutics Corporation is a pharmaceutical manufacturing company. The Company specializes in improving the clinical implementation of active pharmaceutical ingredients (APIs) through local drug delivery and personalized medicines. Crism Therapeutics serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Crism Therapeutics (CRTX LN)

Hybridan Small Cap Feast: 1 June 2026

The UK clinical-stage drug delivery Company focused on the localised and sustained delivery of chemotherapy drugs has been awarded a grant.

Hybridan

Hybridan Small Cap Feast: 21 April 2026

There is continued strong execution across its platform portfolio, which is entering a key inflection point, with multiple products transitioning...

Hybridan

Friday Take Away: 16 January 2026

Post a reverse in May 2024 at 11p into Amur Minerals, this UK clinical stage implantable drug delivery Company is focused on the localised and...

Hybridan

Mothercare plc - Small Cap Feast: 21 September 2026

The supplier of sustainable wood building materials provided a trading update for the five months ended 31 August. Accsys reported revenue of EUR...

Hybridan

Hybridan Small Cap Feast: 13 August 2026

he clinical stage biotech Company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)